beclometasone dipropionate + formoterol fumarate + glycopyrronium bromide

CHF 5993 (marketed under the brand name Trimbow) is an extrafine, fixed-dose triple combination inhaled therapy developed by Chiesi Farmaceutici for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It contains three active ingredients: beclometasone dipropionate (an inhaled corticosteroid that reduces airway inflammation), formoterol fumarate (a long-acting beta-2 adrenergic agonist that promotes bronchodilation), and glycopyrronium bromide (a long-acting muscarinic antagonist that prevents bronchoconstriction). Formulated to deliver extrafine particles that reach both central and peripheral airways, CHF 5993 is administered via a pressurized metered dose inhaler (pMDI) or a dry powder inhaler (DPI) to improve lung function and reduce exacerbations in patients whose symptoms are inadequately controlled by dual therapies.

Brand names

RiarifyTrimbowTrydonis

Other names

Administration via pressurized metered dose inhaler (pMDI)beclometasone + formoterol + glycopyrroniumbeclometasone dipropionate + formoterol fumarate + glycopyrronium bromidebeclometasone dipropionate/formoterol fumarate/glycopyrronium bromidebeclometasone/formoterol/glycopyrroniumbeclometasone/formoterol/glycopyrronium bromide